Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell transplantation for severe autoimmune diseases: progress and problems

A M Marmont1

  • 1II Division of Hematology, S. Martino's Hospital, Genoa, Italy.

Haematologica
|October 30, 1998
PubMed
Summary

Hematopoietic stem cell transplantation (HSCT) shows promise for treating autoimmune diseases (AID). While allogeneic HSCT offers potential graft-versus-autoimmunity, risks remain high; autologous HSCT is safer but may not achieve complete cures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A New Combination of Idarubicin, Etoposide and Cytarabine in Untreated Acute Non-Lymphoblastic Leukemia.

Leukemia & lymphoma·2016
Same author

Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA).

Bone marrow transplantation·2014
Same author

Sjögren's syndrome associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) treated with autologous and subsequently allogeneic haematopoietic SCT (HSCT).

Bone marrow transplantation·2013
Same author

Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE.

Clinical and experimental rheumatology·2011
Same author

Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome.

Autoimmunity·2006
Same author

Pure white cell aplasia (PWCA) relapsing after allogeneic BMT and successfully treated with nine DLIs.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2006

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Autoimmune Disease Research

Background:

  • Animal models have long been used to study and treat autoimmune diseases (AID).
  • Recent advances include human lymphocyte xenografts in SCID mice and allogeneic stem cell transplantation (SCT) for established AID.
  • Mixed allogeneic chimerism has prevented and reversed autoimmune insulitis in NOD mice.

Purpose of the Study:

  • To evaluate the efficacy of hematopoietic stem cell transplantation (HSCT) in treating various autoimmune diseases.
  • To compare the outcomes of allogeneic and autologous HSCT for autoimmune conditions.
  • To explore the potential of novel conditioning regimens for severe, refractory AID.

Main Methods:

  • Review of animal models and clinical data, including the EBMT/EULAR Registry.

Related Experiment Videos

  • Analysis of allogeneic SCT, mixed allogeneic chimerism, and autologous HSCT (using marrow or blood).
  • Consideration of total body irradiation (TBI) and non-myeloablative conditioning regimens.

    • Main Results:

    • Allogeneic SCT can potentially cure AID and exert a graft-versus-autoimmunity effect, but transplant-related mortality (TRM) is a concern.
    • Autologous HSCT has shown favorable results in multiple sclerosis and systemic lupus erythematosus, but less so in refractory autoimmune thrombocytopenic purpura.
    • Complete cures with autologous HSCT are challenging; remissions and reduced autoimmune potential are more realistic goals.

    Conclusions:

    • Allogeneic HSCT holds promise for AID resolution but requires safer protocols to mitigate TRM.
    • Autologous HSCT is a safer alternative, with achievable goals including remissions rather than complete cures.
    • Further prospective randomized studies are needed to compare HSCT efficacy against existing immunosuppressive therapies for severe AID.